QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=F814328285108F7A4EA0DA28CFE696D7;jsessionid=502E776C630F24248151AAEED05D5B46;jsessionid=FE390919606FA9CDF00B0C61A4202833;jsessionid=61D0838D45F2925C0D585C1866D267A3;jsessionid=7F316537DA02218A4A797FAF2426869F;jsessionid=5DC00CBC01CEB2AF1934BA37A199E03F;jsessionid=D4FE74BDDEA41B75AFC606EBD24A977F;jsessionid=9C91D554614C992048811CDA3AC095C8;jsessionid=89EEFE37E7E9182499CCF6C2A62444FA (gene)

1. Ataxin-2 sequesters Raptor into aggregates and impairs cellular mTORC1 signaling.
2. ATXN2 is a target of N-terminal proteolysis.
3. A Case of Coexistent Spinocerebellar Ataxia Type 2 and Primary Progressive Multiple Sclerosis-Coinci…
4. ATXN2 intermediate expansions in amyotrophic lateral sclerosis.
5. TDP-43 impairs sleep in Drosophila through Ataxin-2-dependent metabolic disturbance.

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=F814328285108F7A4EA0DA28CFE696D7;jsessionid=502E776C630F24248151AAEED05D5B46;jsessionid=FE390919606FA9CDF00B0C61A4202833;jsessionid=61D0838D45F2925C0D585C1866D267A3;jsessionid=7F316537DA02218A4A797FAF2426869F;jsessionid=5DC00CBC01CEB2AF1934BA37A199E03F;jsessionid=D4FE74BDDEA41B75AFC606EBD24A977F;jsessionid=9C91D554614C992048811CDA3AC095C8;jsessionid=89EEFE37E7E9182499CCF6C2A62444FA